Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Target Price at $20.20

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned an average rating of “Buy” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $20.20.

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, June 22nd. JMP Securities raised their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 12th. Westpark Capital assumed coverage on Enanta Pharmaceuticals in a research report on Tuesday, September 2nd. They set a “buy” rating and a $24.00 price objective for the company. HC Wainwright assumed coverage on Enanta Pharmaceuticals in a research report on Monday, July 28th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Evercore ISI decreased their price objective on Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Monday.

Enanta Pharmaceuticals Trading Up 1.2%

Shares of ENTA opened at $7.54 on Monday. The business’s 50-day moving average price is $7.86 and its 200 day moving average price is $6.79. The stock has a market capitalization of $161.21 million, a P/E ratio of -1.75 and a beta of 0.84. Enanta Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $13.37.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The firm had revenue of $18.31 million for the quarter, compared to analysts’ expectations of $16.21 million. On average, research analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its holdings in shares of Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 5,779 shares during the last quarter. US Bancorp DE acquired a new stake in shares of Enanta Pharmaceuticals during the 1st quarter valued at about $36,000. GAMMA Investing LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 1st quarter valued at about $40,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter valued at about $88,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter valued at about $66,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.